Linda Martin
Research
Clinical Trials:
NCT04062708 Alliance Foundation Trial 46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Lung Cancer. Study Chair.
NCT03604991: ECOG-ACRIN EA2174, “A Phase II Study of Peri-operative Nivolumab and lpilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma. Principal Investigator: Jennifer Eads.
Role: Alliance Study Champion/National Co-Chair.
NCT 02856581 Alliance Trial A211401 Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients with Newly Diagnosed Lung Cancer Who Smoke Cigarettes (closed)
NCT02468024 Stablemates Trial: Sublobar Resection vs. SBRT for high risk operable early stage lung cancer (closed)
NCT03425643 Keynote 671: Efficacy and Safety of Pembrolizumab with Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants with Resectable stage IIB or IIIA Non-Small Cell Lung Cancer (closed)
NCT02194738 ALCHEMIST Trial and related trials (ANVIL, et al.)
NCT03228537 SWOG 1619: Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma (closed)
NCT04241315 ELUCIDATE: Enabling LUng Cancer IDentification Using folATE Receptor Targeting. On Target Laboratories. Steering Committee, site PI. (closed)